Sökning: WFRF:(Addeo Alfredo) >
Selpercatinib in RE...
-
Illini, OliverKarl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.
(författare)
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
2021-06-11
-
Sage Publications,2021
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-456145
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456145URI
-
https://doi.org/10.1177/17588359211019675DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178982URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Karl Landsteiner Institute for Lung Research and Pulmonary Oncology
-
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naive, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n = 8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade > 3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Hochmair, Maximilian JohannesKarl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.
(författare)
-
Fabikan, HannahKarl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.
(författare)
-
Weinlinger, ChristophKarl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.
(författare)
-
Tufman, AmandaLMU Munchen, Klinikum Univ Muenchen, Med Klin & Poliklin, Mitglied Deutsch Zentrums Lungenforsch, CPC M, Munich, Bayern, Germany.
(författare)
-
Swalduz, AurelieCtr Leon Berard, Lyon, France.
(författare)
-
Lamberg, KristinaUppsala universitet,Lung- allergi- och sömnforskning,Uppsala Univ Hosp, Sweden(Swepub:uu)krila642
(författare)
-
Hashemi, Sayed M. S.Vrije Univ Amsterdam, Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands.,Department of Pneumology, Ordensklinikum Elisabethinen Linz, Linz, Austria
(författare)
-
Huemer, FlorianLudwig Boltzmann Inst Lung Hlth, Dept Resp Care, Klin Penzing, Vienna, Austria.
(författare)
-
Vikström, AndersLinkoping Univ Hosp, Pulm clin, Linkoping, Sweden.,Region Östergötland, Lungmedicinska kliniken US(Swepub:liu)andvi77
(författare)
-
Wermke, MartinTech Univ Dresden, Med Fac C G Carus, NCT UCC Early Clin Trial, Unit Dresden, Dresden, Germany.
(författare)
-
Absenger, GudrunMed Univ Graz, Dept Oncol, Graz, Austria.
(författare)
-
Addeo, AlfredoUniv Hosp Geneva, Oncol Dept, Geneva, Switzerland.
(författare)
-
Banerji, ShantanuUniv Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.
(författare)
-
Calles, AntonioUniv Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain.
(författare)
-
Clarke, StephenRoyal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.
(författare)
-
Di Maio, MassimoUniv Turin, Dept Oncol, Turin, Italy.;Ordine Mauriziano Hosp, Med Oncol, Turin, Italy.
(författare)
-
Durand, AliceUniv Lyon, France Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Canc Inst Lyon,Louis Pradel Hosp,Resp Dept, Lyon, France.
(författare)
-
Duruisseaux, MichaelHosp Civils Lyon, Canc Inst, Louis Pradel Hosp, Resp Dept, Lyon, France.;Canc Res Ctr Lyon, Oncopharmacol Lab, Lyon, France.;Univ Lyon, Univ Claude Bernard Lyon 1, Lyon, France.
(författare)
-
Itchins, MalindaRoyal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.
(författare)
-
Kääränien, Okko-SakariKuopio Univ Hosp, Ctr Canc, Kuopio, Finland.
(författare)
-
Krenn, FlorianLKH Hochsteiermark Standort Leoben, Abt Lungenkrankheiten, Leoben, Austria.
(författare)
-
Laack, EckartStudiengesellschaft Hamatoonkol Hamburg, Hamburg, Germany.
(författare)
-
de Langen, Adrianus JohannesNetherlands Canc Inst, Amsterdam, Netherlands.
(författare)
-
Mohorcic, KatjaUniv Clin Goln, Med Oncol Unit, Golnik, Slovenia.
(författare)
-
Pall, GeorgUniv Innsbruck Hosp, Dept Internal Med V Hematol Oncol, Innsbruck, Austria.
(författare)
-
Passaro, AntonioEuropean Inst Oncol IRCCS, Div Thorac Oncol, Milan, Italy.
(författare)
-
Prager, GeraldComprehens Canc Ctr Vienna, Dept Med I, Vienna, Austria.
(författare)
-
Rittmeyer, AchimLKI Lungenfachklin Immenhausen, Dept Thorac Oncol, Immenhausen, Germany.
(författare)
-
Rothenstein, JeffreyR.S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Adjunct Assistant Professor Queen’s University, Ontario, Canada
(författare)
-
Schumacher, Michael
(författare)
-
Woell, EwaldDepartment Internal Medicine, St. Vinzenz Krankenhaus Betriebs GmbH, Sanatoriumstr. 43, 6511 Zams, Austria
(författare)
-
Valipour, ArschangDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna
(författare)
-
Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY: Sage Publications131758-83401758-8359
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Illini, Oliver
-
Hochmair, Maximi ...
-
Fabikan, Hannah
-
Weinlinger, Chri ...
-
Tufman, Amanda
-
Swalduz, Aurelie
-
visa fler...
-
Lamberg, Kristin ...
-
Hashemi, Sayed M ...
-
Huemer, Florian
-
Vikström, Anders
-
Wermke, Martin
-
Absenger, Gudrun
-
Addeo, Alfredo
-
Banerji, Shantan ...
-
Calles, Antonio
-
Clarke, Stephen
-
Di Maio, Massimo
-
Durand, Alice
-
Duruisseaux, Mic ...
-
Itchins, Malinda
-
Kääränien, Okko- ...
-
Krenn, Florian
-
Laack, Eckart
-
de Langen, Adria ...
-
Mohorcic, Katja
-
Pall, Georg
-
Passaro, Antonio
-
Prager, Gerald
-
Rittmeyer, Achim
-
Rothenstein, Jef ...
-
Schumacher, Mich ...
-
Woell, Ewald
-
Valipour, Arscha ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
THERAPEUTIC ADVA ...
- Av lärosätet
-
Uppsala universitet
-
Linköpings universitet